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Background/aim: The aim of this study is to study subclinical platelet activation by detecting three important platelet activation
parameters of mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) in patients with branch retinal
vein occlusion (BRVO) in comparison to those in healthy control subjects.
Materials and methods: This prospective study included 43 patients with BRVO (Group 1) and 40 control subjects (Group 2). The levels
of MPV, PDW, and PCT were measured in both of the studied groups.
Results: The mean serum level of MPV value was 7.64 ± 0.64 in Group 1 and 7.39 ± 0.42 in Group 2. Mean serum level of PDW was
15.01 ± 1.56 in Group 1 and 14.43 ± 1.03 in Group 2. Mean serum PCT value was 0.19 ± 0.05 in Group 1 and 0.16 ± 0.04 in Group 2.
MPV, PDW, and PCT levels were significantly increased in BRVO patients (P < 0.05).
Conclusion: Subclinical platelet activation reflected by MPV, PDW, and PCT may have an impact on the genesis of vessel occlusion in
BRVO. The results may be important for the clinical management of patients with BRVO.
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1. Introduction
Retinal venous occlusion is the second most common
retinal vascular disorder after diabetic retinopathy
causing visual loss (1). Branch retinal vein occlusion
(BRVO) is a frequent retinal vascular disease with a yearly
incidence of 2.14/1000 in the population over 40 years of
age (2). BRVO is predisposed via various systemic and
local factors (2). Hypertension and end-organ damage
caused by diabetes mellitus contribute to arteriosclerosis,
atherosclerosis, and endothelial dysfunction, which seem
to be major risk factors for BRVO (3). Ophthalmic risk
factors are ocular hypertension, glaucoma, higher ocular
perfusion pressure, and changes in the retinal arteries (4).
Underlying mechanisms for etiopathogenesis of BRVO are
degenerative changes of the vessel wall, compression of
the vein by arteriole at the arteriovenous (AV) crossing,
and disturbed hematological factors (5). Endothelial
dysfunction and platelet activation lead to occlusion of
branch retinal veins (6,7).
Platelets have a very important role in the regulation
of hemostasis and vascular integrity. Platelet indices
such mean platelet volume (MPV), platelet distribution

width (PDW), and plateletcrit (PCT) are standard
indicators of platelet function in disease pathophysiology.
The alterations in platelet parameters may affect the
prothrombotic status of a patient. The platelet markers
have been associated with several pathological conditions,
such as increased levels of MPV shown as a risk factor for
myocardial infarction and stroke (8,9). In a recent study,
MPV was also shown to be increased in BRVO patients
(10). To the best of our knowledge, the platelet activation
parameters including PDW and PCT have not been
studied in BRVO patients previously. The aim of this study
is to assess the possible interrelationships of BRVO with
platelet indices MPV, PDW, and PCT in order to detect
subclinical platelet activation.
2. Materials and methods
This study was carried out with 43 patients with BRVO
between September 2013 and January 2015. All procedures
adhered to the tenets of the Declaration of Helsinki, and
local approval was received from the Ethical Committee
of Ankara Dışkapı Training and Research Hospital.
Informed consent was obtained from each patient after
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explanation of the research purposes. All patients were
Turkish Caucasians. This study is registered with the
Australian New Zealand Clinical Trials Registry, number
ACTRN12616001246471.
The patients were included within two study groups
based on the findings of clinical ocular examination.
The first group included 43 BRVO patients (Group 1);
the second group included 40 adult subjects serving as
controls with no history of ocular and systemic disease
except for hypertension and diabetes mellitus (Group 2).
There were no personal or familial histories of thrombotic
disease in the patients and control cases. The absence
of thrombotic events or a family history of thrombosis
was confirmed by means of a verified questionnaire.
Patients and controls using any medication including
corticosteroid and immunosuppressive therapy, who
had smoking or drinking habits, or who had a history of
systemic inflammatory and ocular disease were excluded.
All of the patients and controls had normal liver and renal
function tests and electrolytes. In order to standardize the
hemostatic system parameter measurements, all sampling
procedures were performed in the morning hours with
fasting. The blood was collected in EDTA vacuum tubes
with minimum stasis and examined within 60 min.
A complete ophthalmological examination including
best corrected visual acuity, intraocular pressure
measurement with Goldmann applanation tonometry,
biomicroscopic examination, and dilated pupil
examination of the posterior segment was performed in
both groups. Subclinical BRVO was not observed in the
control group.
The statistical analysis was performed by t-test
according to Bonferroni procedures for multiple

comparisons. The significance level was determined as P
< 0.05. Differences between two groups for age and sex
were evaluated using Mann–Whitney U tests. All statistics
in this study were analyzed using SPSS 18.0 for Windows
(SPSS Inc., Chicago, IL, USA).
3. Results
Eighty-three individuals were included in this clinical
research. There were 49 women (59.1%) and 34 men
(40.9%). The mean age was 59.6 ± 8.1 years (mean ± SD)
in Group 1 and 61.3 ± 12.8 in Group 2. There were no
difference in terms of age or sex (P = 0.5) (Table 1).
Of the 43 BRVO patients, 25 (58.1%) had hypertension
and 12 (27.9%) had diabetes mellitus. The coexistence
of hypertension and diabetes mellitus was present in
6 patients (13.9%). The location of vein occlusion was
superotemporal in 28 eyes (65.1%), inferotemporal in
14 (32.5%), and inferonasal in 1 (2.3%). The mean bestcorrected visual acuity was 20/80 (range: 20/2000 to 20/25)
in the BRVO group. Biochemical parameters including
glucose, lipid, and homocysteine values and clotting,
plasma viscosity, and inflammatory markers were normal.
Of the 40 control subjects, 20 (52.5%) had hypertension,
9 (22.5%) had diabetes, and 4 (10%) had both hypertension
and diabetes mellitus.
MPV levels showed a marked elevation in our BRVO
patients (P = 0.03) compared with controls. The mean
serum level of MPV was 7.64 ± 0.64 in Group 1 and 7.39 ±
0.42 in Group 2 (Table 2).
Increments in the serum level of PDW were observed
in BRVO cases (P = 0.01) when compared to the control
group. The mean serum level of PDW was 15.01 ± 1.56 in
Group 1 and 14.43 ± 1.03 in Group 2 (Table 2).

Table 1. Demographic data of the groups.
Group 1
(n = 43)

Group 2
(n = 40)

P

Age (years)

61.37 ± 12.87

59.65 ± 8.15

0.47

Sex (male/female)

18/25

16/24

0.17

Table 2. The mean values of mean platelet volume, plateletcrit, and platelet distribution
width and comparison of platelet parameters (mean ± standard deviation) for groups.
Group 1
(n = 43)

Group 2
(n = 40)

P

MPV (fL)

7.64 ± 0.64

7.39 ± 0.42

0.03

PDW (%)

15.01 ± 1.56

14.43 ± 1.03

0.01

PCT (%)

0.19 ± 0.05

0.16 ± 0.04

0.04

MPV: Mean platelet volume, PDW: platelet distribution width, PCT: plateletcrit.
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The mean PCT levels were 0.19 ± 0.05 in BRVO cases,
and these were significantly higher than in controls (0.16
± 0.04; P = 0.04) (Table 2).
4. Discussion
Branch retinal vein occlusion is a common cause of
retinal vascular disorder and is said to be the second most
common disease after diabetic retinopathy (11). Major
pathogenetic factors confined to the pathogenesis of BRVO
are abnormal hematological parameters, degenerative
changes of the retinal vessel wall, and compression
of the retinal vein at the AV crossing (12). Although
multiple hematological parameters were discussed in the
pathogenesis of BRVO, the role of coagulation parameters
remains unclear. Thrombosis may develop due to platelet
abnormalities, endothelial injury, increased procoagulant
activity, and abnormal fibrinolysis. Larger platelets are
more active and contain more intense granules and they
have more powerful prothrombotic activity (13).
Increased MPV may have a role in the vessel occlusion
process of BRVO. Platelet activation also correlates with
increased MPV levels. The high value of MPV is an
indication of increased thrombocyte size. Large platelets
as diameters are more active, functional, and dense than
small ones. Thus, higher MPV levels may increase the
possibility of vascular complications (14,15). Previous
studies showed that MPV was associated with situations
such as coronary and peripheral artery disease, myocardial
infarction, and cerebral ischemia (16–19).
PDW is also related to platelet activation and it is a
more specific marker than MPV, because blood values
of PDW are not high during simple platelet swelling
(20). PDW shows variations in platelet size that may be
indicators of active platelet release (21). PDW levels could
be altered in several conditions and increased levels were
observed in sickle cell patients with vaso-occlusive crisis
(22,23). PDW may be a more specific marker than MPV
for showing platelet activation and increased levels of PDW
might show impaired deformability of thrombocytes and
be related to microvascular resistance (24–26). Vagdatli et
al. (20) found that PDW is a specific and simple marker
for coagulation activation. Thus, increased PDW levels
could be a risk factor and play a role in the pathogenesis
of BRVO. Amin et al. (23) showed elevated levels of PDW
during vaso-occlusive complications in sickle cell anemia
patients.
PCT is a marker of blood-circulating platelets in a unit
volume. PCT reveals quantitative abnormalities of platelets
and is calculated as platelets × MPV/107 (27). Akpinar et al.
(13) found that PCT had a significant predictive value for
saphenous vein graft disease and emphasized that it could
be used as a marker for antiplatelet therapy to prevent graft
atherosclerosis in patients undergoing bypass surgery.

Onder et al. (10) showed decreased levels of platelets
in hypertensive BRVO patients, but not significantly.
In another previous study, PCT was correlated with
C-reactive protein in chronic inflammatory diseases (28).
An increased MPV level in patients with hypertension and
diabetes mellitus without BRVO was reported previously
(29). Therefore, our control subjects were selected from
among individuals with a history of hypertension and
diabetes mellitus.
In the present study, BRVO patients showed
significantly higher levels of MPV, PDW, and PCT. The
increased levels of these parameters may play a role in
the pathogenesis of BRVO. Increment in these platelet
parameters may increase activation and aggregation of
platelets and increase vasoactive mediators’ secretion
by these platelets such as thromboxane A2, resulting in
vasoconstriction, endothelial dysfunction, and impaired
blood flow, which results in microvascular occlusion.
Some studies suggested that thrombophilic parameters
are altered in groups of patients with BRVO and control
groups (10,30). However, to the best of our knowledge,
PDW and PCT have not been evaluated before in patients
with BRVO.
MPV is calculated by dividing the PCT by the number
of platelets, which is the same calculation as for the mean
red cell volume, namely dividing hematocrit by the red
blood cells, and therefore PCT is analogous to the red cell
hematocrit (31). Red cell indices are widely used in clinics.
On the other hand, platelet indices (other than the platelet
count itself) are probably the most regularly ignored part
of the automated complete blood count parameters (32).
Positive studies and metaanalyses of automated platelet
analyses focusing on coronary heart diseases highlighted
long-term efforts about the validation of those ‘routine’ lab
parameters in eye vessel occlusions including BRVO (33).
The pathogenesis of BRVO includes local
microenvironmental factors, including degenerative
changes of vascular endothelium, compression at the AV
crossing, and others. Systemic hypercoagulable factors of
disturbed hematological factors including platelet activity
may also have impact as a triggering factor. The treatment
of this challenging occlusive event may not rely solely
on antiplatelet drugs. However, we must be aware of the
ongoing subclinical thrombocyte activation during the
clinical management of the patients with BRVO.
Squizzato et al. (34) investigated the best available
evidence on the acute treatment and the secondary
prevention of RVO with antithrombotic and fibrinolytic
drugs. A search of the MEDLINE and EMBASE electronic
databases up to January 2009 was performed. They
suggested that antithrombotic therapy, in particular
low-molecular-weight heparin, may be a part of the
therapeutic armamentarium for patients with recent-onset
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RVO. Houtsmuller et al. (35) established a double-blind
study to evaluate the platelet aggregation inhibiting effect
of ticlopidine on the course of ocular vein occlusions.
They determined that the effect of ticlopidine was most
pronounced in patients with increased platelet aggregation
and least obvious in cases of hyperlipidemia. Hypertension
and diabetes did not apparently influence ticlopidine’s
effects. The platelet aggregation inhibitor ticlopidine was
found effective in the treatment of recent ocular vein
occlusions.
There are several limitations in the present study. The
limited number of patients is the most important limiting
factor. Secondly, this study is based on a simple baseline
determination that may not reflect a patient’s long-term
status.
Based on the results of our present study, BRVO
patients have significantly higher serum levels of MPV,
PDW, and PCT than control subjects. MPV, PDW, and

PCT seem to play an important role in the genesis of
BRVO. Serial measurements of PDW, MPV, and PCT may
be helpful in the diagnosis and prevention of BRVO. The
sudden peak of these markers indicates platelet activation.
The results may be important for the clinical management
of patients with BRVO in everyday clinical practice since
those platelet activation parameters are routinely detected
in complete blood count analyses. Further large-scale and
comprehensive studies are needed to support these results.
Based on the current data, if an ophthalmologist does
have a concern that platelet activation could be impaired
in a patient with BRVO, he or she could share the case
with a hematologist if there is any sign of systemic platelet
activation syndromes that potentially affect any microand/or macrocirculatory vessel systems. Antithrombotic,
antiplatelet,
anticoagulant,
and
profibrinolytic
management strategies should then be determined for the
given patient, as well as the hemostatic follow-up.
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